Home › Compare › GLVNF vs ABBV
GLVNF yields 2857.14% · ABBV yields 3.06%● Live data
📍 GLVNF pulled ahead of the other in Year 1
Combined, GLVNF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GLVNF + ABBV for your $10,000?
Gallant Venture Ltd., an investment holding company, operates as an independent utilities provider in Indonesia. The company operates through Industrial Parks; Utilities; Resort Operations; and Property Development segments. The Industrial Parks segment develops, constructs, operates, and maintains industrial properties in Batam and Bintan Islands with supporting infrastructure activities. The Utilities segment provides electricity, water supply, telecommunications, waste management, and sewage treatment services to the industrial parks and resorts in Batam and Bintan Islands. This segment operates 19 dual fuel fired generators with an installed capacity of approximately 130MW at Batamindo Industrial Park; 6 generators with an installed capacity of approximately 24MW at Bintan Industrial Estate; and 4 generators with an installed capacity of approximately 20MW at Bintan Resorts. The Resort Operations segment offers services to resort operators in Bintan Resort, including ferry services and ferry terminal operations, tour operations, property rental, workers accommodation, security, fire-fighting, medical support, and estate and township maintenance services, as well as facilities required by resort operators. The Property Development segment develops industrial and resort properties in Batam and Bintan Islands. It also offers business management consultancy services; and wholesales hotels, resorts, and golf courses. The company was incorporated in 2003 and is headquartered in Singapore.
Full GLVNF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.